Any content you receive is for information purposes only. Always conduct your own research. |
*Sponsored |
Daily Edge Report Just Put (VNRX) On This Morning's Early Watchlist —Wednesday, March 18, 2026. |
Don't miss the next breakout — get real-time alerts sent straight to your phone! |
Full Coverage Is Starting Right Now—Take A Look At (VNRX) |
While It's Still Early… |
March 18, 2026 |
Check It Out Now: (VNRX) Just Jumped on to Our Early Watchlist—Here's Why |
Dear Reader,
The next wave in diagnostics isn't about adding more tests, it's about getting more answers from the ones already being run. |
Instead of complexity, the edge is shifting toward precision, pulling deeper biological signals from something as routine as a standard blood draw. |
That's where VolitionRx Limited (VNRX) has been quietly positioning itself. |
Behind the scenes, (VNRX) has spent years developing its epigenetics-based platform with scalability in mind. Now, the story appears to be evolving, from pure R&D into a phase where execution, distribution, and real-world adoption begin to take center stage. |
And the updates have been stacking. |
Most recently, (VNRX) announced a new distribution partnership in Japan for its Nu.Q® Discover assays, opening access to a major global life sciences market and extending its reach across the research segment. |
On the chart, (VNRX) has already shown how quickly it can respond when attention rotates in, moving approximately 72% in under two weeks, from around $0.22 on December 29, 2025 to $0.38 on January 8, 2026. |
Since then, action has cooled, with (VNRX) trending more quietly at current levels. Near-term RSI readings have drifted toward what some consider oversold territory, a condition traders sometimes watch for signs of momentum resetting. |
That combination, under-the-radar trading, prior volatility, and continued operational progress, can create setups that shift quickly if attention returns. |
After more than a decade refining its platform, recent milestones, ongoing IP development, and expanding partner activity suggest the broader rollout is beginning to take shape. |
That's why (VNRX) just hit our radar… and why it's topping our watchlist this morning—Wednesday, March 18, 2026. |
And the story isn't developing in isolation. |
Several analysts following the company continue to point to what they see as a notable gap between its current valuation and its longer-term commercial potential, something that may keep (VNRX) on watch as this next phase unfolds. |
Analyst Targets Suggest As Much As 1,300% Upside Potential |
|
Analysts maintain a significantly bullish outlook on (VNRX) compared to its recent range. |
|
Keep reading to see why we're so excited to be highlighting (VNRX) right now. |
Precision Signals, Real-World Detection |
VolitionRx Limited (NYSE American: VNRX) is a diagnostics company focused on developing blood-based tests designed to detect and monitor disease through epigenetic signals, specifically, changes in nucleosome structure that can indicate the presence of cancer and other conditions. |
At the core of its platform is the Nu.Q® technology, which aims to extract clinically relevant information from a standard blood draw. By analyzing circulating nucleosomes, the company is working to provide a minimally invasive alternative to more complex or invasive diagnostic procedures, with potential applications across oncology, sepsis, and other disease areas (volition.com). |
The platform is structured across multiple verticals. In human health, VolitionRx is advancing its Nu.Q® Cancer assays, which are being evaluated for early detection and disease monitoring, alongside programs exploring applications in conditions such as sepsis. In parallel, the company has launched Nu.Q® Vet, a veterinary diagnostic offering designed to detect cancer in companion animals, with commercialization efforts expanding across the U.S. and international markets. |
(VNRX) is also building a research and pharmaceutical services pillar through its Nu.Q® Discover assays, which are used by academic institutions and biopharma companies to study epigenetic changes and support dr-ug development efforts. The company reports a growing base of global customers utilizing these assays across research applications. |
With operations spanning research, clinical development, and commercial rollout, (VNRX) is positioning its platform to scale across multiple diagnostic markets, focusing on accessibility, early detection, and data-driven insights derived from routine blood samples. |
|
Latest Company Updates: New Headlines Driving Momentum |
Recent developments around (VNRX) highlight a steady shift from research into broader commercial execution, with multiple announcements across partnerships, product expansion, and clinical progress. |
In March 2026, (VNRX) announced the first fully automated version of its Nu.Q® Vet Cancer Test in partnership with Fujifilm Vet Systems in Japan. This move enables higher-throughput testing through centralized lab automation—an important step toward scaling volume and meeting growing demand, particularly in a market where over 1,700 veterinary hospitals are already engaged with the platform . |
Just weeks earlier, (VNRX) expanded its global reach by appointing Medical & Biological Laboratories (MBL) as a distributor for its Nu.Q® Discover assays in Japan. This adds another layer to its international distribution network and strengthens its presence in a key life sciences research market . |
On the clinical side, (VNRX) has also reported positive data from its Nu.Q® Vet platform, including studies showing over 80% detection rates for certain cancers in animals with high specificity, supporting its push into routine screening applications . |
Operationally, (VNRX) continues to build toward commercialization. A recent company update highlighted multi-pillar progress across clinical development, partnerships, and early commercial traction, signaling a broader transition toward real-world deployment . |
At the same time, the company secured $2.0M in funding to support ongoing operations and development efforts, adding near-term capital flexibility as it advances its platform. |
Taken together, the recent headline flow reflects a company actively building across multiple fronts, expanding distribution, advancing product capabilities, and progressing toward commercialization. |
Where (VNRX) Could See Its Next Wave of Growth |
The market for early disease detection is immense, and (VNRX) is targeting some of the most burdensome conditions in modern medicine. |
Sepsis alone accounts for approximately one in five deaths globally, and its late detection leads to severe morbidity and high healthcare costs. |
According to recent business reviews, (VNRX) identifies a $2.8B Total Addressable Market (TAM) for early sepsis detection and management. |
The inclusion of the Nu.Q® NETs assay in France's "DETECSEPS" program—a real-world evaluation of early sepsis detection—positions Volition to address a critical gap in emergency care. |
By distinguishing sepsis from non-infectious inflammation, this technology could help clinicians intervene hours earlier, potentially saving countless lives. |
In oncology, the scope is even larger. (VNRX) estimates the annual TAM for lung cancer screening and management at $2.3B, while the broader multi-cancer early detection and liquid biopsy market represents a staggering $22B annual potential within the next decade. |
|
By focusing on "low-cost, high-volume" testing, (VNRX) aims to capture significant share in markets traditionally dominated by expensive, complex sequencing. |
Building the Network While Tightening the Model |
(VNRX) appears to be advancing on two fronts at once, expanding its commercial partnerships while maintaining a disciplined approach to capital as it scales. |
On the partnership side, the company has begun extending its model beyond veterinary diagnostics into human healthcare. In Q3 2025, (VNRX) entered into a research license and exclusive commercial option agreement with Werfen, a global leader in specialized diagnostics, to explore the use of its Nu.Q® platform in managing Antiphospholipid Syndrome (APS). At the same time, management has indicated it is in active discussions with roughly 10 leading diagnostic companies worldwide, pointing to a potential pipeline of future licensing agreements that could include upfront payments and recurring revenue streams. |
Financially, recent results reflect a company focused on efficiency while expanding its reach. For Q3 2025, (VNRX) reported revenue of $0.6M, representing a 32% year-over-year increase. Operating expenses were reduced by 10%, while net cash used in operations declined by 33% compared to the prior year, signaling tighter cost control during a growth phase. |
In addition, a recent public offering generated approximately $6.1M in net proceeds, strengthening the company's capital position as it continues to support the rollout of its human diagnostic programs. Under the leadership of CEO Cameron Reynolds, the strategy appears centered on scaling through partnerships and intellectual property development, while maintaining a capital-efficient operating model. |
Taken together, the approach reflects a company working to balance expansion with financial discipline as it moves deeper into commercialization. |
|
7 Reasons (VNRX) Just Hit The Top Of This Morning's Watchlist—Wednesday, March 18, 2026 |
Proven Volatility Profile: Earlier this year, (VNRX) delivered a 72% move in under two weeks (from $0.22 to $0.38), highlighting how quickly action can shift when interest builds.
Reset Technical Setup: Since that move, shares have cooled and are trending more quietly, with recent RSI levels drifting toward what some traders view as reset or "oversold" conditions.
Wide Analyst Dispersion: Coverage on (VNRX) includes targets that suggest 400% to 1,300% upside potential from its recent range, highlighting a wide gap between analyst models and current levels.
Expanding Global Reach: The company continues to grow its international footprint, including a new distribution agreement in Japan for Nu.Q® Discover, alongside partnerships spanning 20+ countries.
Shift Toward Commercialization: After years of development, (VNRX) is moving into a more execution-driven phase, supported by early commercial orders, reimbursement efforts, and expanding lab access.
Exposure to Large Markets: Targeted segments include sepsis ($2.8B), lung cancer screening ($2.3B), and multi-cancer early detection (projected $22B over the next decade).
Improving Cost Discipline: Recent results show 32% year-over-year revenue growth to $0.6M, alongside a 10% reduction in operating expenses and a 33% decline in net cash usage, reflecting a more capital-efficient approach.
|
Full Coverage Is Starting Right Now—Take A Look At (VNRX) |
While It's Still Early… |
(VNRX) is no longer just a development-stage story. |
After more than a decade building its platform, the company now appears to be moving into a phase where execution, adoption, and real-world use begin to matter as much as the underlying science. |
Recent partnerships, expanding global distribution, and early signs of commercial traction suggest the foundation is being put in place. At the same time, improving cost discipline and a strengthened capital position indicate a more focused approach as the rollout continues. |
Analyst coverage also assigns targets that suggest roughly 400% to 1,300% upside potential from recent levels. |
But with multiple potential catalysts now in motion and (VNRX) trending near the lower end of its recent range, (VNRX) is starting to re-enter the conversation. |
We have all eyes on (VNRX) this morning—Wednesday, March 18, 2026. |
Take a look at (VNRX) while it's still early. |
Also, keep a lookout for our next update—it may be hitting within the next 60-90. |
Sincerely, |
Joel Locke |
Senior Editor |
The Daily Edge Report |
DailyEdgeReport.com ("DailyEdgeReport" or "DER" ) is owned by GG Media Holdings LLC, a multi member limited liability company. Data is provided from third-party sources and DER is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile DER brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. |
Pursuant to an agreement between GG Media Holdings LLC and TD Media LLC, GG Media Holdings LLC has been hired for a period beginning on 03/17/2026 and ending on 03/18/2026 to publicly disseminate information about (VNRX:US) via digital communications. Under this agreement, TD Media LLC has paid GG Media Holdings LLC seven thousand five hundred USD ("Funds"). To date, including under the previously described agreement, GG Media Holdings LLC has been paid fourteen thousand five hundred USD ("Funds"). These Funds were part of the fifty thousand USD funds that TD Media LLC received from a third party named Goldwyn Media LLC who did receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. |
Neither GG Media Holdings LLC, TD Media LLC and their member own shares of (VNRX:US). |
Please see important disclosure information here: https://dailyedgereport.com/disclosure/vnrx-0JYV9/#details |
No comments:
Post a Comment